Liu Hengrui, Weng Jieling
Biocomma Limited, Shenzhen, China.
Department of Pathology, The Second Affiliated Hospital of Guangzhou Medical University, Guangzhou, China.
Front Oncol. 2022 Mar 10;12:858756. doi: 10.3389/fonc.2022.858756. eCollection 2022.
RAD51, a critical protein for DNA repairment, has been found to associate with multiple cancer types, but, so far, a systematic pan-cancer analysis of RAD51 has not been done yet.
Data were obtained from multiple open databases and genetic alteration, gene expression, survival association, functional enrichment, stemness, mutation association, immunity association, and drug therapy association of RAD51were analyzed. A prognostic model of RAD51 for overall glioma was constructed as an example application of RAD51 as a biomarker.
RAD51 was overexpressed in 28 types of cancers and was associated with worse overall survival in 11 cancer types. RAD51 correlated genes were enriched in cell cycle terms. RAD51 was associated with cancer stemness, tumor mutational burden, and multiple immunomodulators in different cancer types. RAD51 expression was different across immune subtypes in 11 cancer types. RAD51 was closely associated with cancer immune microenvironments in some cancer types. Proliferating T cells was the cell type that expressed highest RAD51 across most of the cancer samples analyzed. RAD51 expression had an AUC of over 0.5 in 12 of the 23 ICB subcohorts. The Tumor Immune Dysfunction and Exclusion of 9 cancer types were different between RAD51 high and low groups. RAD51 expression showed negative correlations with the sensitivity of most drugs. A prognostic nomogram was constructed with a high confidence.
RAD51 is a clinical valuable biomarker for multiple cancer types, regarding its potential power for diagnosis, prognosis, and therapeutic prediction.
RAD51是一种对DNA修复至关重要的蛋白质，已发现其与多种癌症类型相关，但迄今为止，尚未对RAD51进行系统的泛癌分析。
从多个开放数据库获取数据，并分析RAD51的基因改变、基因表达、生存关联、功能富集、干性、突变关联、免疫关联和药物治疗关联。构建了整体胶质瘤的RAD51预后模型，作为RAD51作为生物标志物的示例应用。
RAD51在28种癌症类型中过表达，在11种癌症类型中与较差的总生存期相关。RAD51相关基因在细胞周期术语中富集。RAD51在不同癌症类型中与癌症干性、肿瘤突变负担和多种免疫调节因子相关。在11种癌症类型中，RAD51表达在免疫亚型之间存在差异。在某些癌症类型中，RAD51与癌症免疫微环境密切相关。在分析的大多数癌症样本中，增殖性T细胞是RAD51表达最高的细胞类型。在23个ICB亚组中的12个中，RAD51表达的AUC超过0.5。RAD51高表达组和低表达组之间9种癌症类型的肿瘤免疫功能障碍和排除情况不同。RAD51表达与大多数药物的敏感性呈负相关。构建了具有高可信度的预后列线图。
就RAD51在诊断、预后和治疗预测方面的潜在能力而言，它是多种癌症类型具有临床价值的生物标志物。
